Survival rates in patients with the newly diagnosed glioblastoma: Data from the National Cancer Registry of Ukraine, 2008-2016

Abstract

Objective. In the current study, we present the results of the survival analysis of patients with newly diagnosed glioblastoma (GBM) in Ukraine.Materials and methods. A total of 3763 cases of patients with histologically confirmed newly diagnosed GBM who were treated over a 9-year period (2008 – 2016) were included. All patients were grouped as younger adults (64 years) – 669 (17.8%). Clinical parameters and survival rates were defined for every three 3-year periods: 2008-2010, 2011-2013, and 2014-2016.Results. The overall median survival was 12.2±0.2 months. Higher survival rate was observed in young adults 17.4±1.4 months (p<0.001). The hazard ratio (HR) of middle-aged group was 1.79 (95% CI 1.60-2.00; p=0.017) and for older age – 1.51 (95% CI 1.32-1.72; p<0.001). The patients treated in the second period achieved better prognosis with a median survival in 12.6±0.3 months (p<0.001) with HR 0.75, 95% CI 0.66-0.85; p<0.01). The median overall survival in combined treatment protocol group was 16.3±0.5 months, and the worst prognosis was in surgery alone group – 7.5±0.3 months (p<0.001). The HR for surgery with radiotherapy was 1.36 (95% CI 1.22-1.51; p<0.001), and for surgery alone it raised up to 1.94 (95% CI 1.73-2.17; p<0.001). The HR for a combination of surgery with chemotherapy was 1.18 (95% CI 0.90-1.53; p<0.001), but it was not significant (p=0.25).Conclusions. The using of combined treatment including surgery and chemoradiotherapy was associated with survival advantage for all age groups and time periods.